Figure 2.

Two–dimensional risk stratification for serious infection and rejection. The risk for rejection and infection was calculated for each patient in the Efficacy Limiting Toxicity Elimination Symphony Study (study arms A–C; n=1190) and displayed in a two-dimensional plot (x axis, rejection; y axis, infection). The two–dimensional risk space was divided in four quadrants by an average patient. The panels indicate the influences of (A) age, (B) donor type, (C) cytomegalovirus (CMV) status, and (D) HLA mismatches on the individual risk profile. BPAR, biopsy–proven acute rejection; CMV D+/R−, high risk for CMV disease with a seropositive donor and a seronegative recipient; EDC, extended criteria donor.